Portal de investigación
Cyclin E cytoplasmatic isoform to predict outcome and benefit to capecitabine treatment in patients with HR+/HER2-metastatic breast cancer from the GEICAM/2013-02 PEARL study
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Guerrero, Angel
- Gil, Miguel J. Gil
- Zielinski, Christoph
- Ruiz-Borrego, Manuel
- Ciruelos, Eva M.
- Munoz, Montserrat
- Murillo, Laura
- Murillo, Serafin Morales
- Alba, Emilio
- Lang, Istvan
- Martinez, Lourdes Calvo
- Vazquez, Manuel Ramos
- De La Haba, Juan
- Herranz, Jesus
- Gal-Yam, Einav Nili
- Alvarez, Isabel
- Garcia-Palomo, Andres
- Rojo, Federico
- Martin, Miguel
Abstract
Abstract no disponible
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Guerrero,A,Gil,MJG,Zielinski,C,Ruiz,M,Ciruelos,EM,Munoz,M,Murillo,L et al. Cyclin E cytoplasmatic isoform to predict outcome and benefit to capecitabine treatment in patients with HR+/HER2-metastatic breast cancer from the GEICAM/2013-02 PEARL study. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). 2023. Chicago. TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103:LIPPINCOTT WILLIAMS & WILKINS. 2023.